In a report released on October 28, Mark Massaro from BTIG reiterated a Buy rating on MDxHealth S.A. Sponsored ADR (MDXH – Research Report), with a price target of $14.00. The company’s shares closed last Friday at $7.01.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, MDxHealth S.A. Sponsored ADR, and Exact Sciences. According to TipRanks, Massaro has an average return of -4.0% and a 40.52% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MDxHealth S.A. Sponsored ADR with a $17.50 average price target.
Based on MDxHealth S.A. Sponsored ADR’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company’s patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Read More on MDXH: